id: NEW:acamprosate_treatment_to_alcohol_use_disorder
name: Acamprosate Treatment â†’ Alcohol Use Disorder
from_node:
  node_id: NEW:acamprosate_treatment
  node_name: Acamprosate Treatment
to_node:
  node_id: alcohol_use_disorder
  node_name: Alcohol Use Disorder
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Acamprosate is prescribed as pharmacotherapy for patients with alcohol
  use disorder, typically in conjunction with psychosocial interventions'
- 'Step 2: Acamprosate modulates glutamatergic neurotransmission and restores the
  balance between excitatory and inhibitory neurotransmitter systems disrupted by
  chronic alcohol use'
- 'Step 3: This neurobiological stabilization reduces alcohol craving and the negative
  affective states associated with protracted abstinence'
- 'Step 4: Patients receiving acamprosate treatment demonstrate significantly higher
  rates of maintaining abstinence (NNT=11 to prevent one person from returning to
  any drinking)'
- 'Step 5: Sustained abstinence and reduced drinking leads to improved alcohol use
  disorder outcomes and reduced severity of the condition'
evidence:
  quality_rating: A
  n_studies: 118
  primary_citation: 'Melissa McPheeters et al. 2023. "Pharmacotherapy for Alcohol
    Use Disorder: A Systematic Review and Meta-Analysis." Journal of the American
    Medical Association (JAMA).'
  supporting_citations: []
description: Acamprosate treatment significantly reduces the likelihood of returning
  to any drinking in patients with alcohol use disorder. A comprehensive meta-analysis
  of 118 clinical trials with 20,976 participants found that acamprosate has a number
  needed to treat of 11 to prevent one person from returning to any drinking, supporting
  its use as a first-line pharmacotherapy for alcohol use disorder when combined with
  psychosocial interventions.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 11.0
    type: number_needed_to_treat
    ci_lower: 1.0
    ci_upper: 32.0
  p_value: null
  sample_size: 20976
moderators:
- name: psychosocial_intervention_co-treatment
  direction: strengthens
  strength: moderate
  description: Acamprosate is recommended for use in conjunction with psychosocial
    interventions, which may enhance treatment efficacy
- name: gastrointestinal_adverse_effects
  direction: weakens
  strength: weak
  description: Diarrhea risk ratio of 1.58 (95% CI, 1.27-1.97) compared to placebo
    may affect adherence and treatment continuation
